|
Market Closed -
Nasdaq
16:00:00 2026-08-21 EDT
|
5-day change | 1st Jan Change | ||
| 24.92 USD | -0.12% |
|
+2.13% | +50.94% |
| 08-07 | UBS Adjusts Price Target on Denali Therapeutics to $34 From $25, Maintains Buy Rating | MT |
| 08-07 | Wedbush Adjusts PT on Denali Therapeutics to $27 From $26, Maintains Outperform Rating | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| DENALI THERAPEUTICS INC. | Bio Therapeutic Drugs | -0.12% | +2.13% | +50.94% | +63.62% | -49.08% | 3.98B |  |  | |
- Stock Market
- Stocks
- DNLI Stock
- Charts Denali Therapeutics Inc.
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
